What is the cost utility analysis of specialist natriuretic peptide monitoring for patients over the age of 75 with CHF and LVSD?
One cost utility analysis found that specialist natriuretic peptide monitoring was cost effective compared to specialist clinical assessment for patients over the age of 75 with CHF and LVSD, with an ICER of 5,392 per QALY gained.